Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.

Alirocumab yields mortality benefits in acute coronary syndrome

04 Jun 2019

The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome (ACS), especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.

The trial randomized 18,924 patients, who had an ACS 1–12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy, to receive either alirocumab or placebo. Treatment dose was blindly titrated to achieve LDL-C targets (25–50 mg/dL). Outcomes of interest were all-cause death and its components, cardiovascular and noncardiovascular death.

Over a median follow-up of 2.8 years, 334 patients (3.5 percent) in the alirocumab group and 392 (4.1 percent) in the placebo group died (hazard ratio [HR], 0.85, 95 percent CI, 0.73–0.98; p=0.03). This survival advantage with the study drug was attributed to nonsignificantly fewer cardiovascular (2.5 percent vs 2.9 percent; HR, 0.88, 0.74–1.05; p=0.15) and noncardiovascular deaths (1.0 percent vs 1.3 percent; HR, 0.77, 0.59–1.01; p=0.06).

In the group of 8,242 patients who completed ≥3 years of follow-up, alirocumab conferred significant protection against death (HR, 0.78, 0.65–0.94; p=0.01). Of note, patients with nonfatal cardiovascular events were at increased risk of cardiovascular and noncardiovascular deaths (p<0.0001), but treatment with alirocumab led to a lower incidence of total nonfatal cardiovascular events (p<0.001) and might have thus attenuated the number of noncardiovascular deaths.

Posthoc analysis revealed that patients with baseline LDL-C ≥100 mg/dL had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71, 0.56–0.90; p-interaction=0.007) compared with those who had lower LDL-C. The risk of all-cause death decreased in alirocumab-treated patients who achieved LDL-C target (approximately 30 mg/dL) at 4 months of treatment (p-trend=0.017).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 11 Jun 2019
The novel antibody-drug conjugate enfortumab vedotin showed promising clinical activity in patients with advanced and metastatic urothelial cancer for whom there is a high unmet need, according to the EV-201 study presented at the ASCO 2019 Meeting.